NCT04040322已完成3 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 198
- 试验地点
- 30
- 主要终点
- Change in Frequency of Symptomatic RP Attacks
研究概览
简要总结
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects must be greater than or equal to 18 years of age.
- •Subjects must have a diagnosis of Systemic Sclerosis as defined by the 2013 American College of Rheumatology criteria/EULAR criteria
- •Subjects must have a diagnosis or history of Raynaud's Phenomenon, self-reported or reported by a physician, with at least a 2-phase color change in finger(s) of pallor, cyanosis, and/or reactive hyperemia in response to cold exposure or emotion
- •Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks, documented in the electronic patient-reported outcomes (ePRO) diary, occurring over at least 3 separate days of the 3- to 5-day eligibility period
- •Subjects must complete a minimum of 80% of the daily ePRO diary entry during the baseline period
- •Female subjects of childbearing potential and male subjects must agree to use contraception for the duration of the study.
- •Subjects must be willing and able to comply with the study requirements and give informed consent for participation in the study
排除标准
- •Female subjects who are pregnant or breastfeeding
- •Subjects with systolic blood pressure <85 mmHg
- •Subjects with an estimated glomerular filtration rate <15 mL/min/1.73 m2
- •Subjects with an alanine aminotransferase and/or aspartate aminotransferase value >3 × the upper limit of normal at screening
- •Subjects who have a digital ulcer infection within 30 days of screening
- •Subjects with a history of cervical or digital sympathectomy, or botulism toxin injections in their hands [for RP or digital ulcers] within 90 days of screening. Subjects should not have a planned botulism toxin or sympathectomy during their participation in the study.
- •Subjects with gangrene or digital amputation within 6 months of screening
- •Subjects with current intractable diarrhea or vomiting
- •Subjects with a risk of clinically significant bleeding events, including those with coagulation or platelet disorders at screening
- •Subjects with a history of major trauma or hemorrhage within 30 days of screening.
- •Subjects with clinically significant chronic intermittent bleeding, such as active gastric antral vascular ectasia or active peptic ulcer disease, within 60 days of screening
- •Subjects who have had any cerebrovascular events (eg, transient ischemic attack or stroke) within 6 months of screening
- •Subjects with a history of myocardial infarction or unstable angina within 6 months of screening. Subjects should not have a planned coronary procedure during their participation in the study
- •Subjects with acute or chronic congestive heart failure (New York Heart Association Class III [moderate] or Class IV [severe]) at screening
- •Subjects with a history of more than mild restrictive or congestive cardiomyopathy uncontrolled by medication or implanted device
- •Subjects with a history of life-threatening cardiac arrhythmias
- •Subjects with a history of hemodynamically significant aortic or mitral valve disease
- •Subjects with a history of known pulmonary hypertension, pulmonary arterial hypertension, or pulmonary veno-occlusive disease
- •Subjects with a history of significant restrictive lung disease, defined as forced vital capacity <45% predicted and diffusing capacity of the lungs for carbon monoxide <40% predicted (uncorrected for hemoglobin)
- •Subjects with scleroderma renal crisis within 6 months of screening
- •Subjects with a concomitant life-threatening disease with a life expectancy <12 months
- •Subjects who have a clinically significant disorder that, in the opinion of the Investigator, could contraindicate the administration of study drug, affect compliance, interfere with study evaluations, or confound the interpretation of study results
- •Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists (eg, epoprostenol, treprostinil, iloprost, and selexipag) within 8 weeks of screening
- •Subjects who have initiated or had a dose change of any of the following within 2 weeks of screening: oral, topical, or intravenous (IV) vasodilators (eg, calcium channel blockers, phosphodiesterase-5 (PDE5) inhibitors [eg, sildenafil, tadalafil, or vardenafil], nitrates, and fluoxetine)
- •Subjects with any history of acetaminophen intolerability (eg, allergic reaction to acetaminophen)
- •Subjects with any malignancy that requires treatment during the study period, that has required treatment within 1 year of screening (including excision of skin cancer) or that is currently not in remission
- •Subjects who have used any investigational medication or device for any indication within 30 days or 5 half-lives (whichever is longer)
- •Subjects who have participated in ES-201 or ES-301 studies and were randomized and treated with study drug
研究组 & 干预措施
Placebo
Placebo Comparator
Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
干预措施: Placebo IV infusion (Drug)
Iloprost Injection, for intravenous use
Active Comparator
Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
干预措施: Iloprost Injection, for intravenous use (Drug)
结局指标
主要结局
Change in Frequency of Symptomatic RP Attacks
时间窗: From baseline (Day 10 to Day 25 of screening period) to the end ofthe efficacy follow-up (Day 8 to Day 21).
The primary efficacy parameter is the change in the weekly frequency of symptomatic RP attacks from baseline. The baseline weekly frequency of symptomatic RP attacks was defined as the average number of weekly symptomatic RP attacks that occurred during the 10- to 25-day baseline ePRO diary completion period. The double-blind endpoint weekly frequency of symptomatic RP attacks was defined as the average number of weekly symptomatic RP attacks that occurred during Days 8 to 21, inclusive
次要结局
- Change in Severity of RP Attack Symptoms(From baseline (Day 10 to Day 25 of screening period) to the end of the efficacy follow-up (Day 8 to Day 21).)
- Weekly Total Duration of Symptomatic RP Attacks.(From baseline (Day 10 to Day 25 of screening period) to the end of the efficacy follow-up (Day 8 to Day 21).)
- Percentage of Responders(From baseline (Day 10 to Day 25 of screening period) to the end of the efficacy follow-up (Day 8 to Day 21).)
研究者
研究点 (30)
Loading locations...
相似试验
招募中
3 期
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated PainEndometriosisNCT05648669Qilu Pharmaceutical (Hainan) Co., Ltd.336
终止
3 期
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisNCT03398837Corbus Pharmaceuticals Inc.365
已完成
3 期
Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisDermatomyositisNCT03813160Corbus Pharmaceuticals Inc.176
已完成
3 期
SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney DiseaseRenal Anemia in Non-dialysis Chronic Kidney DiseaseNCT06016036Shenzhen Salubris Pharmaceuticals Co., Ltd.156
招募中
3 期
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPrimary Generalized Tonic-Clonic SeizuresNCT05667142Xenon Pharmaceuticals Inc.160